Although follow-up is shorter, it appears that the time-limited combination of venetoclax and BTK inhibition, with or without an anti-CD20 does not obviate the long-term negative prognostic impact of TP53 aberrations in patients with treatment-I CLL [79]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.